AbbVie execs have finally gotten around to doing what a host of analysts managed to accomplish long ago: writing down the value of their once much-vaunted cancer drug Rova-T.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,